Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
BACKGROUND: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer. PATIENTS AND METHODS: Patients with ovarian cancer that had relapsed and...
Những tác giả chính: | Zweifel, M, Jayson, G, Reed, N, Osborne, R, Hassan, B, Ledermann, J, Shreeves, G, Poupard, L, Lu, S, Balkissoon, J, Chaplin, D, Rustin, G |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
2011
|
Những quyển sách tương tự
-
Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
Bằng: Zweifel, M, et al.
Được phát hành: (2009) -
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
Bằng: Rustin, G, et al.
Được phát hành: (2010) -
Phase IB dose-escalation and expansion study of AKT kinase inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer
Bằng: Blagden, S, et al.
Được phát hành: (2018) -
Evaluation of retinal nerve fibre layer and macular thickness pre-and post-chemotherapy with carboplatin and paclitaxel in patients with endometrial and ovarian cancer
Bằng: Juen, Chin Ju
Được phát hành: (2021) -
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
Bằng: Nathan, P, et al.
Được phát hành: (2012)